USPTO serial 88167507
TANNQUILYNNE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 18, 2021
- Examiner
- VAGHANI, MAYUR C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with TANNQUILYNNE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SyneuRx International (Taiwan) Corp.
New Taipei City, TW
Other trademarks owned by SyneuRx International (Taiwan) Corp.
SyneuRx International (Taiwan) Corp.
New Taipei City, TW
Other trademarks owned by SyneuRx International (Taiwan) Corp.
SyneuRx International (Taiwan) Corp.
New Taipei City, TW
Other trademarks owned by SyneuRx International (Taiwan) Corp.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael T. Smith
Michael T. Smith BIRCH STEWART KOLASCH & BIRCH LLP8110 Gatehouse Road, Suite 100 EastFalls Church, VA 22042UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Syrups for pharmaceutical purposes for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations for the treatment and prevention of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Transdermal patches for use in the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Natural dietary supplements for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SyneuRx International (Taiwan) Corp.
- Other trademarks owned by SyneuRx International (Taiwan) Corp.
- Other trademarks owned by SyneuRx International (Taiwan) Corp.
- Other trademarks in Class 005
- Similar marks named TANNQUILYNNE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 18, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 18, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 2, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 2, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 10, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 31, 2020 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Dec 31, 2020 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Oct 29, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 28, 2020 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Oct 28, 2020 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Oct 28, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 18, 2020 | APET | ASSIGNED TO PETITION STAFF | — |
| Sep 18, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 10, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 10, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 10, 2020 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Jul 24, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 24, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 24, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 24, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 24, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 24, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 29, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 27, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 27, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 27, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 15, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 13, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 13, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 13, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 12, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 15, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 15, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 26, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 7, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 7, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 6, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 27, 2018 | NWAP | NEW APPLICATION ENTERED | — |